Genfit Stock Price, News & Analysis (NASDAQ:GNFT) $3.18 -0.08 (-2.45%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$3.18▼$3.1950-Day Range$2.97▼$3.4052-Week Range$2.89▼$4.75Volume37,487 shsAverage Volume39,008 shsMarket Capitalization$158.46 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Genfit MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside135.8% Upside$7.50 Price TargetShort InterestBearish0.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.23) to $0.50 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.72 out of 5 starsMedical Sector705th out of 952 stocksBiological Products, Except Diagnostic Industry115th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingGenfit has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Genfit has a forecasted upside of 135.8% from its current price of $3.18.Amount of Analyst CoverageGenfit has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.22% of the float of Genfit has been sold short.Short Interest Ratio / Days to CoverGenfit has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Genfit has recently increased by 0.57%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGenfit does not currently pay a dividend.Dividend GrowthGenfit does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNFT. Previous Next N/A News and Social Media Coverage Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genfit insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of Genfit is held by insiders.Percentage Held by InstitutionsOnly 8.82% of the stock of Genfit is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Genfit are expected to grow in the coming year, from ($0.23) to $0.50 per share.Price to Book Value per Share RatioGenfit has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Genfit Stock (NASDAQ:GNFT)Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Read More GNFT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNFT Stock News HeadlinesNovember 17, 2023 | benzinga.comGENFIT Highlights ACLF Development Strategy at "ACLF Day" during AASLD The Liver Meeting® 2023November 9, 2023 | finance.yahoo.comGENFIT Reports Third Quarter 2023 Financial InformationDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 9, 2023 | msn.comOil Stocks Buoy European Equities Traded in the US as American Depositary Receipts ThursdayNovember 7, 2023 | msn.comOil Stocks Burden European Equities Traded in the US as American Depositary Receipts TuesdaySeptember 26, 2023 | finance.yahoo.comGENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic TechnologySeptember 26, 2023 | finance.yahoo.comGENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowSeptember 22, 2023 | finanznachrichten.deGENFIT S.A.: GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate UpdateDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. September 20, 2023 | finance.yahoo.comGENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate UpdateSeptember 15, 2023 | fool.comGenfit (NASDAQ: GNFT)August 16, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Higher WednesdayAugust 14, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Start Week on Down NoteJune 30, 2023 | msn.comGenfit’s Liver Disease Candidate Delivers Promising Phase 3 ResultsJune 16, 2023 | markets.businessinsider.comKepler Capital Keeps Their Buy Rating on Genfit (GNFTF)June 8, 2023 | msn.comPORTZAMPARC BNP PARIBAS Maintains Genfit (EPA:GNFT) Buy RecommendationJune 7, 2023 | finance.yahoo.comGENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023June 1, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Genfit SA (GNFT)May 31, 2023 | finance.yahoo.comSeal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)May 31, 2023 | finance.yahoo.comGENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage AssetMay 23, 2023 | finance.yahoo.comGENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of HepatologyApril 19, 2023 | finance.yahoo.comGENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory DocumentsJanuary 5, 2023 | finance.yahoo.comGENFIT to Participate in Upcoming Investor ConferencesOctober 10, 2022 | benzinga.com12 Health Care Stocks Moving In Monday's Pre-Market Session - Acer Therapeutics (NASDAQ:ACER), Avadel Pha - BenzingaOctober 7, 2022 | marketscreener.comGENFIT : Pipeline Day - Corporate Presentation - October 2022 - Marketscreener.comSeptember 30, 2022 | globenewswire.comGENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis - GlobeNewswireSeptember 28, 2022 | globenewswire.comGENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update - GlobeNewswireSee More Headlines Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNFT CUSIPN/A CIK1757064 Webwww.genfit.com Phone(332) 016-4000FaxN/AEmployees154Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$11.00 Low Stock Price Target$4.00 Potential Upside/Downside+135.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.91 Current Ratio2.95 Quick Ratio2.95 Sales & Book Value Annual Sales$28 million Price / Sales5.66 Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book1.59Miscellaneous Outstanding Shares49,830,000Free Float47,742,000Market Cap$158.46 million OptionableNot Optionable Beta1.08 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Jean-Francois Mouney (Age 68)Co-Founder & Chairman of the Board Comp: $401.85kMr. M. Pascal Prigent (Age 55)Chief Executive Officer Comp: $609.01kProf. Bart Staels (Age 60)Co-Founder & Chairman of the Scientific Advisory Board Mr. Thomas Baetz (Age 49)Chief Financial Officer Mr. Pascal Caisey (Age 55)Chief Operating Officer Dr. Meriam Kabbaj Ph.D. (Age 49)Chief Technology Officer Dr. Dean W. Hum Ph.D. (Age 61)Chief Scientific Officer Comp: $774.94kMr. Jean-Christophe Marcoux (Age 45)Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG Mr. Laurent Lannoo (Age 53)Corporate Secretary & Director of Legal Affairs Ms. Stefanie Magner J.D. (Age 42)Chief Compliance Officer & Executive VP of International Legal Affairs More ExecutivesKey CompetitorsMolecular PartnersNASDAQ:MOLNERYTECH PharmaNASDAQ:ERYPDBV TechnologiesNASDAQ:DBVTINmune BioNASDAQ:INMBInvivydNASDAQ:IVVDView All CompetitorsInstitutional OwnershipO Shaughnessy Asset Management LLCSold 18,822 shares on 11/14/2023Ownership: 0.027%View All Institutional Transactions GNFT Stock Analysis - Frequently Asked Questions Should I buy or sell Genfit stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GNFT shares. View GNFT analyst ratings or view top-rated stocks. What is Genfit's stock price target for 2024? 2 brokers have issued 1 year target prices for Genfit's stock. Their GNFT share price targets range from $4.00 to $11.00. On average, they predict the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 135.8% from the stock's current price. View analysts price targets for GNFT or view top-rated stocks among Wall Street analysts. How have GNFT shares performed in 2023? Genfit's stock was trading at $4.3890 at the beginning of 2023. Since then, GNFT stock has decreased by 27.5% and is now trading at $3.18. View the best growth stocks for 2023 here. What is Jean-François Mouney's approval rating as Genfit's CEO? 3 employees have rated Genfit Chief Executive Officer Jean-François Mouney on Glassdoor.com. Jean-François Mouney has an approval rating of 29% among the company's employees. This puts Jean-François Mouney in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Genfit own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), STAG Industrial (STAG), Gilead Sciences (GILD), Occidental Petroleum (OXY), Vaxart (VXRT), Exxon Mobil (XOM), Zynerba Pharmaceuticals (ZYNE), Aimmune Therapeutics (AIMT) and Amarin (AMRN). When did Genfit IPO? (GNFT) raised $132 million in an IPO on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers. Who are Genfit's major shareholders? Genfit's stock is owned by a number of institutional and retail investors. Top institutional shareholders include O Shaughnessy Asset Management LLC (0.03%). How do I buy shares of Genfit? Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:GNFT) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.